Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment
2011/09/13 by Suzanne Craft · 31 citations
Pharmacology, Toxicology and Pharmaceutics · Neuroscience · #Advanced Drug Delivery Systems #Olfactory and Sensory Function Studies #Neurological Disorders and Treatments
paper · doi:10.1001/archneurol.2011.233
Abstract
OBJECTIVE: To examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and cerebrospinal fluid biomarkers in adults with amnestic mild cognitive impairment or Alzheimer disease (AD). DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Clinical research unit of a Veterans Affairs medical center. PARTICIPANTS: The intent-to-treat sample consisted of 104 adults with amnestic mild cognitive impairment (n = 64) or mild to moderate AD (n = 40). Intervention Participants received placebo (n = 30), 20 IU of insulin (n = 36), or 40 IU of insulin (n = 38) for 4 months, administered with a nasal drug delivery device (Kurve Technology, Bothell, Washington). MAIN OUTCOME MEASURES: Primary measures consisted of delayed story recall score and the Dementia Severity Rating Scale score, and secondary measures included the Alzheimer Disease's Assessment Scale-cognitive subscale (ADAS-cog) score and the Alzheimer's Disease Cooperative Study-activities of daily living (ADCS-ADL) scale. A subset of participants underwent lumbar puncture (n = 23) and positron emission tomography with fludeoxyglucose F 18 (n = 40) before and after treatment. RESULTS: Outcome measures were analyzed using repeated-measures analysis of covariance. Treatment with 20 IU of insulin improved delayed memory (P < .05), and both doses of insulin (20 and 40 IU) preserved caregiver-rated functional ability (P < .01). Both insulin doses also preserved general cognition as assessed by the ADAS-cog score for younger participants and functional abilities as assessed by the ADCS-ADL scale for adults with AD (P < .05). Cerebrospinal fluid biomarkers did not change for insulin-treated participants as a group, but, in exploratory analyses, changes in memory and function were associated with changes in the Aβ42 level and in the tau protein-to-Aβ42 ratio in cerebrospinal fluid. Placebo-assigned participants showed decreased fludeoxyglucose F 18 uptake in the parietotemporal, frontal, precuneus, and cuneus regions and insulin-minimized progression. No treatment-related severe adverse events occurred. CONCLUSIONS: These results support longer trials of intranasal insulin therapy for patients with amnestic mild cognitive impairment and patients with AD. Trial Registration clinicaltrials.gov Identifier: NCT00438568.
Cited by
- Glucagon-like peptide-1 signaling in learning and memory: evidence, mechanisms, and therapeutic implications
- Nose-to-Brain Delivery
- Mechanism of intranasal drug delivery directly to the brain
- Signaling pathways driving multiple sclerosis: From mechanisms to natural‑product interventions
- A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease
- Ageing as a Risk Factor for Disease
- Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. [europepmc]
- Intranasal treatment of central nervous system dysfunction in humans. [europepmc]
- A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. [europepmc]
- Alzheimer's disease and insulin resistance: translating basic science into clinical applications. [europepmc]
- Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. [europepmc]
- Damaging effects of a high-fat diet to the brain and cognition: a review of proposed mechanisms. [europepmc]
- Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. [europepmc]
- Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. [europepmc]
- Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. [europepmc]
- Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease. [europepmc]
- Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. [europepmc]
- Oxidative and nitrative stress in neurodegeneration. [europepmc]
- Aberrant insulin signaling in Alzheimer's disease: current knowledge. [europepmc]
- HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment. [europepmc]
- Drug treatments in Alzheimer's disease. [europepmc]
- In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. [europepmc]
- Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study. [europepmc]
- Insulin Resistance and Alzheimer's Disease: Bioenergetic Linkages. [europepmc]
- Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. [europepmc]
- Altered Insulin Signaling in Alzheimer's Disease Brain - Special Emphasis on PI3K-Akt Pathway. [europepmc]
- Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. [europepmc]
- The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics. [europepmc]
- Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. [europepmc]
- Role of Insulin in Health and Disease: An Update. [europepmc]
- Insulin and Insulin Resistance in Alzheimer's Disease. [europepmc]
Related